Business Context and Reporting Period
This Form 8-K is a current report filed by Protalix Biotherapeutics, Inc. on May 10, 2012. The filing serves as a Regulation FD disclosure to announce upcoming presentations by senior management at three investor and industry conferences.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is informational regarding corporate events and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces scheduled conference appearances.
Guidance, Outlook, and Management Commentary
Management has scheduled presentations at the following events:
- The Oppenheimer 13th Annual Israeli Conference: Sunday, May 13, 2012, at 1:00 PM IDT in Tel-Aviv, Israel.
- The TASE & NASDAQ OMX 5th Annual Investor Conference: Thursday, May 17, 2012, at 11:00 AM EDT in New York, NY.
- The ILSI-Biomed 2012 Conference: Monday, May 21, 2012, at 12:30 PM IDT in Tel-Aviv, Israel.
The press release accompanying this filing is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the content of the press release (Exhibit 99.1) for specific details on the company's strategic updates to be discussed at the conferences.
- Confirm the dates and times of the three announced conference presentations to schedule attendance or listen to webcasts.
- Note that this filing contains no new financial data; investors should refer to the most recent 10-K or 10-Q for financial metrics.